Device Trial Radar · NCT00180349
Leader - Evaluation of Endotak Reliance
Last checked: Nov 20, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
904
Actual
Start
Dec 2004
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to demonstrate the efficacy of the ENDOTAK® RELIANCE™ defibrillation leads connected to a defibrillator or a cardiac resynchronization defibrillator from implant until 12 months.
Conditions
- Ventricular Tachycardia
- Ventricular Fibrillation
Interventions
Endotak RelianceDevice
Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Defibrillation testing (DT) procedures and consequences on clinical outcomesTime frame: at implant
- Defibrillation testing (DT) procedures and consequences on clinical outcomesTime frame: during 1 year follow-up
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
CH Amiens
Amiens, France
CHU Angers
Angers, France
Hôpital Angoulème
Angoulème, France
22 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.